ARENTFOX SCHIFF LLP for EQRX INTERNATIONAL, INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues and policies impacting innovation in drug development S. 908 (Medicare Drug Price Negotiation Act), all provisions S. 909 (Prescription Drug Price Relief Act of 2021), all provisions S. 1427 (Increasing Access to Biosimilars Act of 2021), regarding Centers for Medicare and Medicaid Services Innovation Center shared savings demonstration projects H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act), all provisions Draft legislation (21st Century Cures Act 2.0), regarding innovation in drug development S. 1898 (Affordable Medications Act), all provisions Health Savings Accounts generally H.R. 5376 (Build Back Better Act), Title XIII, Subtitle J, regarding drug pricing H.R. 5801 (HELP Copays Act), all provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| BYRON DORGAN | — |
| DAN RENBERG | — |
| OLIVER SPURGEON III | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.